Clinical Trial Update: Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas [Phase 2]

View source ↗

Summary

Phase 2 trial investigating durvalumab with booster radiation in metastatic pancreatic adenocarcinoma was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Baptist Health South Florida | Conditions: Adenocarcinoma of the Pancreas | Phase 2 | Status: TERMINATED | Results posted: 2023-10-12